Solutions
Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
Insights
Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.
Our Solutions
News and Events
5th Annual Immuno-Oncology BD&L and Investment Forum
Speaker: Roger Longman
Real Endpoints
Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.
May 31, 2019
Waldorf Astoria Chicago Hotel
Jeff Berkowitz Takes Helm of Real Endpoints
by PharmaVoice
Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.
AMCP Nexus
Attendee: Real Endpoints team
The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.
Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?
by Richard Mark Kirkner
The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?
Recent Insights
view archive >
November 18, 2018
What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system
Amid national angst over prescription drug pricing, Express Scripts is touting a new scheme it says will lessen the behind-the-scenes role that rebates play in rising costs. In effect, Express Scripts would create a two-tier system for its customers which could choose between a formulary with a high list price and high rebate, or the newer plan that will offer a lower list price and lower or no rebate.
read full insight article >
November 5, 2018
Backing into Value with Part B
Jeff Berkowitz, CEO, Real Endpoints' is quoted, "It becomes a global index that reflects the value as seen by number of different entities against all of the other choices they need to make from a health delivery perspective."
read full insight article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.